Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In chronic kidney disease (CKD), accumulation of uremic toxins is associated with an increased risk of CKD progression. Some uremic toxins result from nutrient processing by gut microbiota, yielding precursors of uremic toxins or uremic toxins themselves, such as trimethylamine N-Oxide (TMAO), p-cresyl sulphate, indoxyl sulphate and indole-3 acetic acid. Increased intake of some nutrients may modify the gut microbiota, increasing the number of bacteria that process them to yield uremic toxins. Circulating levels of nutrient-derived uremic toxins are associated to increased risk of CKD progression. This offers the opportunity for therapeutic intervention by either modifying the diet, modifying the microbiota, decreasing uremic toxin production by microbiota, increasing toxin excretion or targeting specific uremic toxins. We now review the link between nutrients, microbiota and uremic toxin with CKD progression. Specific focus will be placed on the generation specific uremic toxins with nephrotoxic potential, the decreased availability of bacteria-derived metabolites with nephroprotective potential, such as vitamin K and butyrate and the cellular and molecular mechanisms linking these toxins and protective factors to kidney diseases. This information provides a conceptual framework that allows the development of novel therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H. C., Rolph, M. S., Mackay, F., Artis, D., et al. (2009) · Nature · doi:10.1038/nature08530 · Cited by 3,241 · cited 1×
“Butyrate is a general inhibitor of histone deacetylases (HDAC) and protects against high-fat diet-induced metabolic changes [105], has anti-inflammatory properties [106], extends lifespan in experimental progeria mice [107] and protects from features of aging such as sarcopenia, which are prominent in CKD [108].”
BackgroundBrown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409
Butyrate improves insulin sensitivity and increases energy expenditure in mice
Gao, Z., Yin, J., Zhang, J., Ward, R. E., Martin, R. J., Lefevre, M., Cefalu, W. T., & Ye, J. (2009) · Diabetes · doi:10.2337/db08-1637 · Cited by 2,204 · cited 1×
“Butyrate is a general inhibitor of histone deacetylases (HDAC) and protects against high-fat diet-induced metabolic changes [105], has anti-inflammatory properties [106], extends lifespan in experimental progeria mice [107] and protects from features of aging such as sarcopenia, which are prominent in CKD [108].”
BackgroundYancey, P. H. (2005) · Journal of Experimental Biology · doi:10.1242/jeb.01730 · Cited by 1,868
The microbiology of butyrate formation in the human colon
Pryde, S. E., Duncan, S. H., Hold, G. L., Stewart, C. S., & Flint, H. J. (2002) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2002.tb11467.x · Cited by 1,320
Tang, W. H. W., Wang, Z., Kennedy, D. J., Wu, Y., Buffa, J. A., Agatisa-Boyle, B., Li, X. S., Levison, B. S., & Hazen, S. L. (2015) · Circulation Research · doi:10.1161/circresaha.116.305360 · Cited by 1,223 · cited 7×
“In an independent study, feeding mice a high fat diet increased TMAO levels as well as kidney tubulointerstitial fibrosis and collagen deposition, SMAD3 phosphorylation, KIM-1, plasma cystatin C and evidence of inflammation, such as NOX-4 and TNF-α.”
BackgroundInfluentialBennett, B. J., Vallim, T. Q. D. A., Wang, Z., Shih, D. M., Meng, Y., Gregory, J., Allayee, H., Lee, R., Graham, M., Crooke, R., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.011 · Cited by 1,070
Advanced glycoxidation end products in commonly consumed foods
Goldberg, T., Cai, W., Peppa, M., Dardaine, V., Baliga, B. S., Uribarri, J., & Vlassara, H. (2004) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2004.05.214 · Cited by 744
The contributory role of gut microbiota in cardiovascular disease
Tang, W. H. W., & Hazen, S. L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72331 · Cited by 641
Cited by
Microbiota in health and diseases
Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00974-4 · Cited by 3,171
The Controversial Role of Human Gut Lachnospiraceae
Vacca, M., Celano, G., Calabrese, F. M., Portincasa, P., Gobbetti, M., & De Angelis, M. (2020) · Microorganisms · doi:10.3390/microorganisms8040573 · Cited by 1,688
The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease
Zhu, H., Cao, C., Wu, Z., Zhang, H., Sun, Z., Wang, M., Xu, H., Zhao, Z., Wang, Y., Pei, G., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.06.014 · Cited by 274
Postbiotics: metabolites and mechanisms involved in microbiota-host interactions
Peluzio, M. D. C. G., Martinez, J. A., & Milagro, F. I. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2020.12.004 · Cited by 139
Human gut microbiome: the hypothesis of a gut-muscle axis in the elderly
Ticinesi, A., Tana, C., Nouvenne, A., & Meschi, T. (2018) · Deutsche Zeitschrift für Sportmedizin · doi:10.5960/dzsm.2018.355 · Cited by 4
Metadata
- Authors
- Castillo-Rodriguez, E., Fernandez-Prado, R., Esteras, R., Perez-Gomez, M. V., Gracia-Iguacel, C., Fernandez-Fernandez, B., Kanbay, M., Tejedor, A., Lazaro, A., Ruiz-Ortega, M., Gonzalez-Parra, E., Sanz, A. B., Ortiz, A., & Sanchez-Niño, M. D.
- Venue
- Toxins
- Publisher
- MDPI AG
- Published
- 2018-07-19
- Volume
- 10
- Issue
- 7
- Pages
- 300
- ISSN
- 2072-6651 (ISSN-L)
- OpenAlex
- W2884560868
- Cited by
- 150
- References
- 20
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression. https://app.cochat.ai/papers/10.3390/toxins10070300
- The paper
- Castillo-Rodriguez, E., Fernandez-Prado, R., Esteras, R., Perez-Gomez, M. V., Gracia-Iguacel, C., Fernandez-Fernandez, B., Kanbay, M., Tejedor, A., Lazaro, A., Ruiz-Ortega, M., Gonzalez-Parra, E., Sanz, A. B., Ortiz, A., & Sanchez-Niño, M. D. (2018). Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression. Toxins. https://doi.org/10.3390/toxins10070300
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.